论文部分内容阅读
High-dose therapy followed by autologous hematopoietic stem cell(HSC) transplant is considered standard of care for eligible patients with multiple myeloma. The optimal colection strategy should be effective in procuring sufficient HSC while maintaining a low toxicity profile. Currently available mobilization strategies include growth factors alone,growth factors in combination with chemotherapy,or growth factors in combination with chemokine receptor antagonists; however,the optimal strategy has yet to be elucidated. Herein,we review the risks and benefits of each approach.
High-dose therapy followed by autologous hematopoietic stem cell (HSC) transplant is considered standard of care for eligible patients with multiple myeloma. The optimal colection strategy should be effective in procuring sufficient HSC while maintaining a low toxicity profile. Currently Available mobilization strategies include growth factors alone, growth factors in combination with chemotherapy, or growth factors in combination with chemokine receptor antagonists; however, the optimal strategy has yet to be elucidated. Herein, we review the risks and benefits of each approach.